Allgens Medical Technology Co., Ltd. (688613.SH) Latest Company News

Nov 1, 2026, 13:01 UTC
The China Securities Regulatory Commission opened an investigation into Allgens Medical over suspected false financial data in periodic reports.
Source:
- finance.sina.cn
Oct 30, 2026, 12:25 UTC
Aojing Medical said it would be unable to publish its 2026 third-quarter report by the statutory deadline and postponed disclosure to no later than December 31, 2026.
Source:
- finance.sina.cn
- finance.sina.cn
Sep 21, 2026, 10:03 UTC
Beijing Qilun Tianyou Venture Capital plans to reduce its stake in Allgens Medical by up to 400,000 shares, or 0.29% of total shares, via centralized bidding or block trades between October 22, 2026 and January 22, 2027.
Source:
- finance.sina.cn
Aug 29, 2026, 13:49 UTC
Aojing Medical's self-developed "Aoyuning" absorbable collagen hemostatic sponge obtained a production license, expanded production capacity, and was selected for the Beijing-Tianjin-Hebei "3+N" alliance volume-based procurement catalog.
Source:
- wap.eastmoney.com
Aug 29, 2026, 13:49 UTC
Aojing Medical's rotator cuff repair material product registration application was accepted, entering the sports medicine sector.
Source:
- wap.eastmoney.com
Aug 28, 2026, 12:11 UTC
Beijing Allgens Medical Science Co., Ltd. obtained Thai registration certificate for its artificial bone product OssaNova™ during the first half of 2026.
Source:
- finance.sina.cn
- wap.eastmoney.com
Aug 28, 2026, 12:11 UTC
Beijing Allgens Medical Science Co., Ltd. reported first-half 2026 revenue of 104 million yuan, up 4.03% year-on-year, and R&D investment of 17.41 million yuan, up 10.70%.
Source:
- finance.sina.cn
- wap.eastmoney.com
Jul 24, 2026, 09:43 UTC
Aojing Medical Technology Co., Ltd. announced that as of July 20, 2026, the company has no actual controller.
Source:
- finance.sina.cn
Jul 15, 2026, 13:55 UTC
The workers' congress of Allgens Medical Technology Co., Ltd. removed Cui Han from her position as employee-representative director.
Source:
- wap.eastmoney.com

688613.SH

The China Securities Regulatory Commission opened an investigation into Allgens Medical over suspected false financial data in periodic reports.

Aojing Medical said it would be unable to publish its 2026 third-quarter report by the statutory deadline and postponed disclosure to no later than December 31, 2026.

Beijing Qilun Tianyou Venture Capital plans to reduce its stake in Allgens Medical by up to 400,000 shares, or 0.29% of total shares, via centralized bidding or block trades between October 22, 2026 and January 22, 2027.

Aojing Medical's self-developed "Aoyuning" absorbable collagen hemostatic sponge obtained a production license, expanded production capacity, and was selected for the Beijing-Tianjin-Hebei "3+N" alliance volume-based procurement catalog.

Aojing Medical's rotator cuff repair material product registration application was accepted, entering the sports medicine sector.

Beijing Allgens Medical Science Co., Ltd. obtained Thai registration certificate for its artificial bone product OssaNova™ during the first half of 2026.

Beijing Allgens Medical Science Co., Ltd. reported first-half 2026 revenue of 104 million yuan, up 4.03% year-on-year, and R&D investment of 17.41 million yuan, up 10.70%.

Aojing Medical Technology Co., Ltd. announced that as of July 20, 2026, the company has no actual controller.

The workers' congress of Allgens Medical Technology Co., Ltd. removed Cui Han from her position as employee-representative director.